NeOnc Technologies IR

$NTHI is proud to announce that CEO, Executive Chairman, & President Amir Heshmatpour has invested more than $500K in recent weeks and nearly $1M over the past year. All purchases were made with personal funds & disclosed through SEC Form 4 filings. investors.neonc.com/news-releases/…

@Parkk_Claire (2/2) NeOnc’s therapeutic approach is centered on improving CNS penetration & enabling treatment candidates to reach tumor tissue better. We believe continued progress in targeted delivery technologies may help expand treatment possibilities for patients facing brain tumors.

@Parkk_Claire (1/2) Thank you for highlighting one of the most significant challenges in neuro-oncology. The blood-brain barrier continues to limit the effectiveness of many conventional therapies in aggressive brain cancers, making drug delivery a critical area of innovation.

Brain cancer remains one of the toughest challenges in oncology. Survival rates for aggressive tumors like glioblastoma haven’t meaningfully improved in decades. That’s why companies like NeOnc are taking a different approach.

@JodieRosss (2/2) NeOnc’s development strategy is built around improving CNS delivery & enabling therapeutics to reach the tumor environment. We believe advances in both treatment mechanisms & delivery approaches will be critical to improving outcomes for patients with brain tumors.

@JodieRosss (1/2) As research continues to reinforce the role of tumor metabolism and targeted therapeutics in aggressive brain cancers, overcoming the blood-brain barrier remains one of the field’s central challenges.

New research from Johns Hopkins Kimmel Cancer Center shows that blocking how tumor cells produce energy could slow Group 3 medulloblastoma, an aggressive pediatric brain cancer. Big takeaway: targeting cancer metabolism is promising.

NeOnc Technologies continues to gain momentum. BTIG has initiated coverage with a Buy rating and a $15 PT, led by analyst Thomas Shrader. A strong vote of confidence as we advance innovative therapies for CNS cancers. $NTHI #Biotech #BTIG #BuyRating investors.neonc.com/static-files/3…

NeOnc recently announced approximately $300K in insider purchases of $NTHI stock by its Chairman and CEO, while providing added context on 2025 financial results. A strong vote of confidence that aligns leadership with long-term shareholder value. investors.neonc.com/news-releases/…

NeOnc Technologies $NTHI recently announced approximately $300,000 in open-market stock purchases by Chairman & CEO Amir Heshmatpour, reinforcing management’s alignment with shareholders and confidence in the Company’s long-term strategy. investors.neonc.com/news-releases/…

ICYMI, Watch on YouTube: NeOnc Technologies | One Year on NASDAQ $NTHI | Progress, Pipeline & What’s Next One year after NeOnc's listing on NASDAQ, NeOnc reflects on key clinical and regulatory milestones achieved as a public company. youtube.com/watch?v=uxcjTk…

Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President of #NeOncTechnologies $NTHI, commented on the recent Business Update and Q4 2025 Financial Report:

NeOnc Technologies recently reported Q4 2025 results and highlights of clinical and strategic progress, reflecting continued execution across clinical development, leadership expansion, and strategic positioning heading into the next phase of growth. $NTHI investors.neonc.com/news-releases/…

We’re thrilled to celebrate our CEO, Amir Heshmatpour, being featured in USA Today’s list of Top Entrepreneurs Going Into 2026, a testament to visionary leadership and bold innovation shaping the future of biotech. #Leadership #Entrepreneurship #Biotech usatoday.com/story/special/…

Driving Scientific Innovation into Commercial Impact $NTHI leverages a robust ecosystem of research, regulatory, and management expertise to accelerate the translation of cutting-edge science from the lab to the clinic and into the marketplace. bit.ly/NTTS-NeOncBrea…

NeOnc Technologies | One Year on NASDAQ (NTHI) | Progress, Pipeline & What’s Next One year after NeOnc Technologies' listing on NASDAQ under the ticker $NTHI, NeOnc reflects on key clinical and regulatory milestones achieved as a public company. youtube.com/watch?v=uxcjTk…

A quote from NeOnc Technologies founder, Dr. Thomas Chen, Chief Medical Officer. $NTHI #NeOncTechnologies

$NTHI NeOnc announces the appointment of David Choi as Chief Accounting Officer, strengthening the Company’s financial leadership as it advances its clinical programs targeting central nervous system (CNS) cancers. Welcome to the team, David. investors.neonc.com/news-releases/…

Amir Heshmatpour, Chairman and CEO of $NTHI: ”These early efficacy signals, observed even within a dose-escalation safety study, provide meaningful clinical validation of NEO212’s therapeutic potential.” investors.neonc.com/news-releases/…

NeOnc Technologies invites investors and community members to participate in our upcoming Ask Me Anything (AMA) session, led by a member of NeOnc’s leadership team. 🔗 Watch and comment here: youtube.com/watch?v=O0npxu… #NeOnc #Biotech #BrainCancerResearch #InvestorRelations #AMA

$NTHI NeOnc Technologies reports Phase 1 Results for Oral NEO212 - Live Conference With the recommended Phase 2 dose now established, the program moves forward into Phase 2 clinical development. 🎥 Watch the conference call: lnkd.in/gq2Sh_EK #NeOnc #Biotech #IR

We’re thrilled to celebrate our CEO, Amir Heshmatpour, being featured in USA TODAY's list of Top Entrepreneurs Going Into 2026, a testament to visionary leadership and bold innovation shaping the future of biotech. $NTHI usatoday.com/story/special/…